Oxford Digital Innovation encompasses three different products. Two of them are online health records platform which aim to integrate NHS data (Zygote – IVF platform – and Simba – maternity platform). The 3rd platform is a virtual hospital which is aimed at scheduling appointments for patients and enable online consultations in specific specialisations, starting with eye care, skin care, pathology and dental medicine.

To develop and commercialise a rapid non-lab based diagnostic test for viral infections, with the first focus on Covid19.

Development of a platform for the standardisation of assetments to facility language, reading and arithmetic skills in children.

Revolutionary healthcare technology that measures medical vital signs without physical contact.

Oxford Electromagnetic Solutions - smart asset management through underground network visibility.

Oxidative Enzymes for the Pulp and Paper Industry.

Oxford Advanced Surfaces develops and commercialises advanced materials and technology solutions leveraging breakthrough surface modification technology.

Genetic Genealogy

Specialised archaeological-based IT applications.

Drug Development. Oxford Asymmetry merges with Evotec BioSystems April 2009.

Pollination.

Oxford BioDynamics offers a novel and revolutionary biomarker discovery platform technology in the diagnostics field of aberrant gene expression.

Biomimetic spinning of fibres.

Gene-based Therapeutics.

Water quality monitoring devices based on electrochemical (bio)sensors.

Develops and commercialises enzymatic process technologies that yield high-value chemical compounds.

Software and patented approach to differential diagnosis of cognitive diseases

Pioneering biomarker technologies for cancer therapies.

Oxford Consultants for Social Inclusion (OCSI) helps local government identify deprived neighbourhoods, target resources, evaluate programme effectiveness and strengthen regeneration bids.

Screensavers for drug candidates.